Loading...
 
Επιστροφή στη λίστα
Article Links
Ιn vivo μελέτη της διαπερατότητας του αρθρικού υμένα από σελεκοξίμπη και ετορικοξίμπη και η επίδρασή της στον έλεγχο του πόνου σε ασθενείς με φλεγμονώδη αρθρίτιδα
Αθηνά Θεοδωρίδου1,2, Ελένη Γκίκα3, Ευδοξία Δίζα4, Αλέξανδρος Γαρύφαλλος1, Λουκάς Σέττας2
Πληροφορίες Συγγραφέων

1: Δ' Παθολογική Κλινική, Ιατρική Σχολή Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάδα

2: Τμήμα Ρευματολογίας, Α' Παθολογική Κλινική, Πανεπιστημιακό Νοσοκομείο ΑΧΕΠΑ, Ιατρική Σχολή Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάδα

3: Τμήμα Ιατροδικαστικής Τοξικολογίας, Ιατρική Σχολή Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάδα

4: Τμήμα Μικροβιολογίας, Πανεπιστημιακό Νοσοκομείο ΑΧΕΠΑ, Ιατρική Σχολή Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάδα

Λέξεις Κλειδιά: Φλεγμονώδης αρθρίτιδα, αρθρικό υγρό, δείκτης διαπερατότητας ετορικοξίμπη, σελεκοξίμπη
Πλήρες Κείμενο
Αυτό το άρθρο είναι γραμμένο μόνο στην Αγγλική γλώσσα
Παραπομπές
  1. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
  2. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008;64:233-52.
  3. Forrest M, Brooks P M. Mechanism of action of non-steroidal anti-rheumatic drugs. Baillieres Clin Rheumatol 1988;2:275-94.
  4. Brooks P. Non steroidal anti-inflammatory drugs.  Volume 1, section 4, pg 377, Rheumatology, Third edition. London:Mosby;2003
  5. Lin J H. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 2006;7:39-65.
  6. Day R O, Graham G G, Williams K M. Pharmacokinetics of non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1988;2:363-93.
  7. Graham G G. Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs. Med J Aust 1987;147:597-602.
  8. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anestesiol 2005;71:461-70.
  9. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78.
  10. Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol 2005;1:269-82.
  11. Paulson S K, Hribar J D, Liu N W, Hajdu E, Bible R H Jr, Piergies A, et al. Metabolism and excretion of celecoxib in healthy male volunteers. Drug Metab Dispos 2000;28:308-14.
  12. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 2008;64:233-52.
  13. Davies N M, McLachlan A J, Day R O, Williams K M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225-42.
  14. Kirchheiner J, Störmer E, Meisel C, Steinbach N, Roots I, Brockmöller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003;13:473-80.
  15. Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
  16. Tang C, Shou M, Rushmore T H, Mei Q, Sandhu P, Woolf E J, et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001;11:223-35.
  17. Rodrigues A D, Halpin R A, Geer L A, Cui D, Woolf E J, Matthews C Z, et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003;31:224-32.
  18. Agrawal N G, Porras A G, Matthews C Z, Rose M J, Woolf E J, Musser B J, et al. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;43:268-76.
  19. Gika H G, Theodoridou A, Michopoulos F, Theodoridis G, Diza E, Settas L, et al. Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 2009;49:579-86.
  20. Swartz M E. UPLCTM: An Introduction and Review. J Liq Chrom & Rel Techn 2005;28:1253-63.
  21. Huang J, Hu X, Zhang J, Li K, Yan Y, Xu X. The application of inductively coupled plasma mass spectrometry in pharmaceutical and biomedical analysis. J Pharm Biomed Anal 2006;40:227–34.
  22. Applications and Technology of a New ICP-MS Spectrometer, Atomic Spectroscopy, Special Issue, Vol. 16, No. 1, Jan/Feb, 1995.
  23. Day R O, McLachlan A J, Graham G G, Williams K M. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-10.
  24. Simkin P A, Wu M P, Foster D M. Articular pharmacokinetics of protein-bound antirheumatic agents. Clin Pharmacokinet 1993;25:342-50.
  25. Gaucher A, Netter P, Faure G, Schoeller JP, Gerardin A.  Diffusion of oxyphenbutazone into synovial fluid, synovial tissue, joint cartilage and cerebrospinal fluid. Eur J Clin Pharmacol 1983; 25:107-12.
  26. Farr M, Hawkins C F, Kendall M J, Willis J V. Some observations and speculations on the factors influencing the concentration of phenylbutazone in synovial fluid. Int J Clin Pharmacol Ther Toxicol 1982;20:589-94.
  27. Lapicque F, Vergne P, Jouzeau J Y, Loeuille D, Gillet P, Vignon E, et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo-oxygenase inhibition in synovial cells. Clin Pharmacokinet 2000;39:369-82.
  28. Bannwart B, Bertin P, Péhourcq F, Schaeverbeke T, Gillet P, Lefrançois G, et al. Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin. Int J Clin Pharmacol Ther 2001;39:33-6.
  29. Hinderling P H, Hartmann D, Crevoisier C, Moser U, Heizmann P. Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. Ther Drug Monit 1988;10:250-60.
  30. Day R O, Williams K M, Graham S, Handel M. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Arthritis Rheum 1991;34:751-60.
  31. Nichol F E, Samanta A, Rose C M. Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis. Drugs 1988;35 Suppl 1:46-51.
  32. Tod M, Pobel C, Le Gros V, Louchahi K, Petitjean O, Brion N, et al. A population pharmacokinetic study of alminoprofen penetration into synovial fluid. Biopharm Drug Dispos 1995;16:627-34.
  33. Dittrich P, Köhler G, Primbs P, Kukovetz W R. Pharmacokinetics of indomethacin i.m. in blood, synovial fluid, synovial membrane, muscle, fat, bone, and spinal fluid. Eur J Rheumatol Inflamm 1984;7:45-50.
  34. Deneke J, Luckow V, Guserle R, Pässler H H. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients. Int J Clin Pharmacol Ther 1998;36:418-24.
  35. Bianchi M, Ferrario P, Balzarini P, Broggini M. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006;34:348-54.
  36. Soren A. Kinetics of salicylates in blood and joint fluid. J Clin Pharmacol 1975;15(2-3):173-7.
  37. Hunter R P, Radlinsky M, Koch D E, Corse M, Pellerin M A, Halstead J. Plasma pharmacokinetics and synovial fluid concentrations after oral administration of single and multiple doses of celecoxib in greyhounds. Am J Vet Res 2005;66:1441-5.
  38. Werner U, Werner D, Rau T, Fromm M F, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-7.
  39. Davies N M, Skjodt N M. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach. Clin Pharmacokinet 2000;38:377-92.
  40. Furst D E. Synovial fluid kinetics of non-steroidal anti-inflammatory drugs. Agents Actions Suppl 1985;17:65-78.
  41. Rordorf C M, Choi L, Marshall P, Mangold J B.  Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2005;44:1247-66.
  42. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005;144:538-50.
  43. Mäkelä AL, Lempiäinen M, Ylijoki H.  Ibuprofen levels in serum and synovial fluid. Scand J Rheumatol 1981;10 Sup 39:15-7.
  44. Fowler P D, Shadforth M F, Crook P R, John V A. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 1983;25:389-94.
  45. Emori H W, Champion G D, Bluestone R, Paulus H E. Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis 1973;32:433-5.
  46. Bingham C O 3rd, Sebba A I, Rubin B R, Ruoff G E, Kremer J, Bird S, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007;46:496-507.
  47. Bingham C O 3rd, Bird S R, Smugar S S, Xu X, Tershakovec A M. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis. Osteoarthritis Cartilage 2008;16:1289-93.
  48. Jansen J P, Gaugris S, Choy E H, Ostor A, Nash J T, Stam W. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010;28:323-44.
  49. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005;14:798-804.